2025 Q4 -tulosraportti
Vain PDF
18 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenIT'S GETTING CROWDED AT THE DOOR NOW. MAY IS A PRESSURE COOKER. ⏳🧨 Most in the market can only focus on one thing at a time. Either they are looking at the ASGCT presentations in Boston, or they are looking at VWAP and the warrants. But if you want to understand why May is so brutally exciting for Circio, you need to see how these two timelines are now crashing right into each other. Let's break it down: 1. The Finance Engine (May 8 – 22) 💰 This is the VWAP period for the warrants. For many, it sounds like dry financial mathematics, but it is extremely strategic. Why? Because the share price development during this period determines how attractive it will be to exercise them, which in turn controls how much capital Circio receives. And in biotech, capital is power. Strong capital means runway. It means that Circio does not need to sell its technology at a fire sale, and it gives them negotiating power to demand the best deals when Big Pharma knocks on the door. 2. The Science Engine (May 13 and 15) 🧬🌍 And here's the cherry on top: Right in the middle of this critical financial period, Circio is on stage at ASGCT in Boston. This is not a Shareville webinar. This is the arena where the global elite searches for the next big billion-dollar technology. Those in the audience understand exactly what «60x higher expression in eye» and «22x higher expression at 1/10 of the dose» mean for patient safety and commercial value. They understand the potential of a delivery-agnostic platform. So what happens when these two collide? When the global elite gets the technology confirmed on stage, at the same time as the market prices in the capital structure that will take the company forward... then it gets crowded at the door. When "smart money" (institutions, analysts, partners) wants in, they don't argue about penny fluctuations. They position themselves for the long-term platform game. This does not mean the stock goes straight through the roof on day one. But it means we are entering a month where visibility, capital, and industrial interest meet at one and the same crossroads. It is a "pressure cooker". Patience is easy when you understand the calendar. Brick by brick. We know what we own. ♟️🧱🍷
·3 t sittenWhat do we think about the coming week staying around where we are now before it's going to fly next week when the team is in Boston?- ·3 t sitten · MuokattuWhat appear to be upcoming announcements are: 1. 4.0 in heart. Only 3.2 has been made public. The poster presentation on May 13 concerns heart. See attachment abstract 1 to the April 27 announcement. 4.0 data might be what boosts the poster itself. It also states there that preclinical studies are ongoing in 3 disease models in heart. 2. 3.2 and 4.0 in CNS. Only 2.1 has been published. New results here might come on May 15 in an oral presentation. Boosts that presentation. ASGCT seems to be directed towards gene therapy, not cell therapy / CAR-T. 3. CAR-T. Here they must have something ready internally, given that 2 collaboration projects have been entered into. Most likely in a separate announcement.
·8 t sittenThe GEN article about Circio and TraffikGene confirms, in my opinion, the most important point in the case right now: It's about delivery. GEN describes the collaboration as a combination of Circio's circVec platform and TraffikGene's peptide-amphiphile delivery system, with the goal of more targeted, efficient, and long-lasting non-viral delivery to specific cell and tissue types. That is strategically important. The AAV track shows how circVec can improve classical gene therapy through higher expression and possible dose-sparing. The Acuitas track tests LNP delivery and in vivo CAR-T. The TraffikGene track adds a third route: peptide-based non-viral delivery. This means that Circio does not lock the technology to one delivery platform. They are testing whether circVec can work across multiple delivery systems. This is exactly what can increase the platform's value. The GEN article also points out that the collaboration will proceed step-by-step: first in vitro screening, then optimization of formulations, and finally in vivo testing in mice to assess expression kinetics, biodistribution, and delivery efficacy. In other words: this is still early research, not clinical or commercial validation. But it is a concrete test plan, and it directly addresses one of the biggest bottlenecks in gene and cell therapy. For me, the main point is simple: The engine is circVec. But the value increases significantly if the engine can be placed in multiple vehicles. AAV. LNP. Peptide-based non-viral delivery. This is what Circio is now building — step by step.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
18 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenIT'S GETTING CROWDED AT THE DOOR NOW. MAY IS A PRESSURE COOKER. ⏳🧨 Most in the market can only focus on one thing at a time. Either they are looking at the ASGCT presentations in Boston, or they are looking at VWAP and the warrants. But if you want to understand why May is so brutally exciting for Circio, you need to see how these two timelines are now crashing right into each other. Let's break it down: 1. The Finance Engine (May 8 – 22) 💰 This is the VWAP period for the warrants. For many, it sounds like dry financial mathematics, but it is extremely strategic. Why? Because the share price development during this period determines how attractive it will be to exercise them, which in turn controls how much capital Circio receives. And in biotech, capital is power. Strong capital means runway. It means that Circio does not need to sell its technology at a fire sale, and it gives them negotiating power to demand the best deals when Big Pharma knocks on the door. 2. The Science Engine (May 13 and 15) 🧬🌍 And here's the cherry on top: Right in the middle of this critical financial period, Circio is on stage at ASGCT in Boston. This is not a Shareville webinar. This is the arena where the global elite searches for the next big billion-dollar technology. Those in the audience understand exactly what «60x higher expression in eye» and «22x higher expression at 1/10 of the dose» mean for patient safety and commercial value. They understand the potential of a delivery-agnostic platform. So what happens when these two collide? When the global elite gets the technology confirmed on stage, at the same time as the market prices in the capital structure that will take the company forward... then it gets crowded at the door. When "smart money" (institutions, analysts, partners) wants in, they don't argue about penny fluctuations. They position themselves for the long-term platform game. This does not mean the stock goes straight through the roof on day one. But it means we are entering a month where visibility, capital, and industrial interest meet at one and the same crossroads. It is a "pressure cooker". Patience is easy when you understand the calendar. Brick by brick. We know what we own. ♟️🧱🍷
- ·3 t sittenWhat do we think about the coming week staying around where we are now before it's going to fly next week when the team is in Boston?
- ·3 t sitten · MuokattuWhat appear to be upcoming announcements are: 1. 4.0 in heart. Only 3.2 has been made public. The poster presentation on May 13 concerns heart. See attachment abstract 1 to the April 27 announcement. 4.0 data might be what boosts the poster itself. It also states there that preclinical studies are ongoing in 3 disease models in heart. 2. 3.2 and 4.0 in CNS. Only 2.1 has been published. New results here might come on May 15 in an oral presentation. Boosts that presentation. ASGCT seems to be directed towards gene therapy, not cell therapy / CAR-T. 3. CAR-T. Here they must have something ready internally, given that 2 collaboration projects have been entered into. Most likely in a separate announcement.
- ·8 t sittenThe GEN article about Circio and TraffikGene confirms, in my opinion, the most important point in the case right now: It's about delivery. GEN describes the collaboration as a combination of Circio's circVec platform and TraffikGene's peptide-amphiphile delivery system, with the goal of more targeted, efficient, and long-lasting non-viral delivery to specific cell and tissue types. That is strategically important. The AAV track shows how circVec can improve classical gene therapy through higher expression and possible dose-sparing. The Acuitas track tests LNP delivery and in vivo CAR-T. The TraffikGene track adds a third route: peptide-based non-viral delivery. This means that Circio does not lock the technology to one delivery platform. They are testing whether circVec can work across multiple delivery systems. This is exactly what can increase the platform's value. The GEN article also points out that the collaboration will proceed step-by-step: first in vitro screening, then optimization of formulations, and finally in vivo testing in mice to assess expression kinetics, biodistribution, and delivery efficacy. In other words: this is still early research, not clinical or commercial validation. But it is a concrete test plan, and it directly addresses one of the biggest bottlenecks in gene and cell therapy. For me, the main point is simple: The engine is circVec. But the value increases significantly if the engine can be placed in multiple vehicles. AAV. LNP. Peptide-based non-viral delivery. This is what Circio is now building — step by step.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
18 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenIT'S GETTING CROWDED AT THE DOOR NOW. MAY IS A PRESSURE COOKER. ⏳🧨 Most in the market can only focus on one thing at a time. Either they are looking at the ASGCT presentations in Boston, or they are looking at VWAP and the warrants. But if you want to understand why May is so brutally exciting for Circio, you need to see how these two timelines are now crashing right into each other. Let's break it down: 1. The Finance Engine (May 8 – 22) 💰 This is the VWAP period for the warrants. For many, it sounds like dry financial mathematics, but it is extremely strategic. Why? Because the share price development during this period determines how attractive it will be to exercise them, which in turn controls how much capital Circio receives. And in biotech, capital is power. Strong capital means runway. It means that Circio does not need to sell its technology at a fire sale, and it gives them negotiating power to demand the best deals when Big Pharma knocks on the door. 2. The Science Engine (May 13 and 15) 🧬🌍 And here's the cherry on top: Right in the middle of this critical financial period, Circio is on stage at ASGCT in Boston. This is not a Shareville webinar. This is the arena where the global elite searches for the next big billion-dollar technology. Those in the audience understand exactly what «60x higher expression in eye» and «22x higher expression at 1/10 of the dose» mean for patient safety and commercial value. They understand the potential of a delivery-agnostic platform. So what happens when these two collide? When the global elite gets the technology confirmed on stage, at the same time as the market prices in the capital structure that will take the company forward... then it gets crowded at the door. When "smart money" (institutions, analysts, partners) wants in, they don't argue about penny fluctuations. They position themselves for the long-term platform game. This does not mean the stock goes straight through the roof on day one. But it means we are entering a month where visibility, capital, and industrial interest meet at one and the same crossroads. It is a "pressure cooker". Patience is easy when you understand the calendar. Brick by brick. We know what we own. ♟️🧱🍷
- ·3 t sittenWhat do we think about the coming week staying around where we are now before it's going to fly next week when the team is in Boston?
- ·3 t sitten · MuokattuWhat appear to be upcoming announcements are: 1. 4.0 in heart. Only 3.2 has been made public. The poster presentation on May 13 concerns heart. See attachment abstract 1 to the April 27 announcement. 4.0 data might be what boosts the poster itself. It also states there that preclinical studies are ongoing in 3 disease models in heart. 2. 3.2 and 4.0 in CNS. Only 2.1 has been published. New results here might come on May 15 in an oral presentation. Boosts that presentation. ASGCT seems to be directed towards gene therapy, not cell therapy / CAR-T. 3. CAR-T. Here they must have something ready internally, given that 2 collaboration projects have been entered into. Most likely in a separate announcement.
- ·8 t sittenThe GEN article about Circio and TraffikGene confirms, in my opinion, the most important point in the case right now: It's about delivery. GEN describes the collaboration as a combination of Circio's circVec platform and TraffikGene's peptide-amphiphile delivery system, with the goal of more targeted, efficient, and long-lasting non-viral delivery to specific cell and tissue types. That is strategically important. The AAV track shows how circVec can improve classical gene therapy through higher expression and possible dose-sparing. The Acuitas track tests LNP delivery and in vivo CAR-T. The TraffikGene track adds a third route: peptide-based non-viral delivery. This means that Circio does not lock the technology to one delivery platform. They are testing whether circVec can work across multiple delivery systems. This is exactly what can increase the platform's value. The GEN article also points out that the collaboration will proceed step-by-step: first in vitro screening, then optimization of formulations, and finally in vivo testing in mice to assess expression kinetics, biodistribution, and delivery efficacy. In other words: this is still early research, not clinical or commercial validation. But it is a concrete test plan, and it directly addresses one of the biggest bottlenecks in gene and cell therapy. For me, the main point is simple: The engine is circVec. But the value increases significantly if the engine can be placed in multiple vehicles. AAV. LNP. Peptide-based non-viral delivery. This is what Circio is now building — step by step.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt